B-Raf enzyme inhibitors

Trametinib + dabrafenib - Vemurafenib      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

melanoma

encorafenib plus binimetinib
COLUMBUS, 2018      NCTencorafenib plus binimetinibvemurafenib1LRisk of bias suggesting-46%
trametinib + dabrafenib
Flaherty, 2012      NCTtrametinib and dabrafenibdabrafenibsuggesting-61%
COMBI-D (Long), 2014        NCTtrametinib and dabrafenibdabrafenib1L unresectablesuggesting-25%-37%
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting-53%-43%
COMBI neo, 2018      NCTtrametinib and dabrafenib SOCadjuvant -
COMBI-V (Robert), 2015      NCTtrametinib and dabrafenibvemurafenib1Lsuggesting-44%-31%
vemurafenib
BRIM 8, 2018      NCTvemurafenibplaceboadjuvantsuggesting-35%-28%
vemurafenib and cobimetinib
Larkin, 2014      NCTvemurafenib and cobimetinibvemurafenibsuggesting-49%